Current developments in pharmacological therapeutics for chronic constipation

Acta Pharmaceutica Sinica B

Volumn 5, Issue 4, 2015, Pages 300-309

  Jiang, Chunhuan ^a   Xu, Qinglong ^a   Wen, Xiaoan ^a   Sun, Hongbin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

5 HT4 receptor; Chronic constipation; Prokinetic agent; Prosecretory agent

Indexed keywords

ATRIAL NATRIURETIC FACTOR RECEPTOR; BILE ACID; CHENODEOXYCHOLIC ACID; CHLORIDE CHANNEL STIMULATING AGENT; CHOLIC ACID; COLCHICINE; ELOBIXIBAT; ERYTHROMYCIN; GASTROINTESTINAL AGENT; HERBACEOUS AGENT; HORMONE RECEPTOR STIMULATING AGENT; KWA 0711; LINACLOTIDE; LUBIPROSTONE; MDT 006; MISOPROSTOL; MITEMCINAL; MOTILIN RECEPTOR AGONIST; NARONAPRIDE; PLECANATIDE; PRUCALOPRIDE; SEROTONIN 4 AGONIST; SEROTONIN AGONIST; UNCLASSIFIED DRUG; UROGUANYLIN; VELUSETRAG;

BINDING AFFINITY; CHRONIC CONSTIPATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECALL; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; REVIEW;

EID: 84947202409     PISSN: 22113835     EISSN: 22113843     Source Type: Journal    
DOI: 10.1016/j.apsb.2015.05.006     Document Type: Review

References (63)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006, 130:1480-1491.
2. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:1582-1591.
3. Higgins PD, Johanson JE. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004, 99:750-759.
4. Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther 2010, 31:938-949.
5. Everhart JE, Ruhl CE. Burden of digestive diseases in the united states part II: lower gastrointestinal diseases. Gastroenterology 2009, 136:741-754.
6. Sorbera LA, Castaner J, Mealy NE. Lubiprostone: treatment of constipation, treatment of irritable bowel syndrome, treatment of postoperative ileus, CIC-2 channel activator. Drug Future 2004, 29:336-341.
7. Kamm MA, Müller-Lissner S, Talley NJ, Tack J, Boeckxstaens G, Minushkin ON, et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005, 100:362-372.
8. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002, 71:533-554.
9. 4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ-specific behavior. J Pharmacol Exp Ther 2006, 317:955-964.
10. Müller-Lissner S, Rykx A, Kerstens R, Vandeplassche L. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil 2010, 22:991-998.
11. Tack J, Camilleri M, Chang L, Chey WD, Galligan J, Lacy BE, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012, 35:745-767.
12. Manini ML, Camilleri M, Goldberg M, Sweetser S, McKinzie S, Burton D, et al. Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010, 22:42-49.
13. 4 receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008, 378:125-137.
14. Goldberg M, Li YP, Johanson JF, Mangel AW, Kitt M, Beattie DT, et al. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation-a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther 2010, 32:1102-1112.
15. Beattie DT, Zamora F, Armstrong SR, Pulido-Rios T, Humphrey PP Tegaserod, but not TD-5108, has effects in porcine and canine isolated coronary arteries. Proceedings of the British Pharmacological Society 2007, Dec; Brighton, UK. Available from: 〈http://www.pA2online.org/abstracts/Vol5Issue2abst138P.pdf〉.
16. Dennis D, Palme M, Irwin I, Druzgala P, Teichman S. ATI-7505 is a novel, selective 5HT(4) receptor agonist that causes gastrointestinal prokinetic activity in dogs. Gastroenterology 2004, 126 Suppl 2:A641. 10.1016/S0016-5085(04)80015-5.
17. Palme M, Milner PG, Ellis DJ, Marmon T, Canafax DM. 905A novel gastrointestinal prokinetic, ATI-7505, increased spontaneous bowel movements (Sbms) in a phase II, randomized, placebo-controlled study of patients with chronic idiopathic constipation (CIC). Gastroenterology 2010, 138:S128-S129. S-128-S-129.
18. 4 receptor agonist with gastrointestinal prokinetic properties. Front Pharmacol 2011, 2:25.
19. 2+ signalling induced by motilin and erythromycin in the circular smooth muscle of human colon. Neurogastroenterol Motil 2001, 13:27-35.
20. Weber FH, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993, 88:485-490.
21. Sharma SS, Bhargava N, Mathur SC. Effect of oral erythromycin on colonic transit in patients with idiopathic constipation a pilot study. Dig Dis Sci 1995, 40:2446-2449.
22. Peeters TL. GM-611 (Chugai Pharmaceutical). Curr Opin Investig Drugs 2001, 2:555-557.
23. Sudo H, Ozaki K, Muramatsu H, Kamei K, Yogo K, Cynshi O, et al. Mitemcinal (GM-611), an orally active motilin agonist, facilitates defecation in rabbits and dogs without causing loose stools. Neurogastroenterol Motil 2007, 19:318-326.
24. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov 2009, 8:153-171.
25. Barrett KE, Keely SJ. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu Rev Physiol 2000, 62:535-572.
26. Zifarelli G, Pusch M. CLC chloride channels and transporters: a biophysical and physiological perspective. Rev Physiol Biochem Pharmacol 2007, 158:23-76.
27. Cuppoletti J, Malinowska DH, Tewari KP, Li QJ, Sherry AM, Patchen ML, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004, 287:C1173-C1183.
28. Catalán M, Niemeyer MA, Cid LP, Sepúlveda FV. Basolateral ClC-2 chloride channels in surface colon epithelium: regulation by a direct effect of intracellular chloride. Gastroenterology 2004, 126:1104-1114.
29. Lacy BE, Levy LC. Lubiprostone: a chloride channel activator. J Clin Gastroenterol 2007, 41:345-351.
30. Bijvelds M, Bot AG, Escher JC, De Jonge HR. Activation of intestinal Cl-secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology 2009, 137:976-985.
31. 4. Biochem Biophys Res Commun 2012, 426:374-379.
32. Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010, 55:1090-1097.
33. 2 on intestinal fluid transport and myoelectric spike activity in the dog. Dig Dis Sci 1986, 31:148S.
34. Bukhave K, Rask-Madsen J. Saturation kinetics applied to in vitro effects of low prostaglandin E2 and F 2 alpha concentrations on ion transport across human jejunal mucosa. Gastroenterology 1980, 78:32-42.
35. Soffer EE, Metcalf A, Launspach J. Misoprostol is effective treatment for patients with severe chronic constipation. Dig Dis Sci 1994, 39:929-933.
36. Roarty TP, Weber F, Soykan I, McCallum RW. Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial. Aliment Pharmacol Ther 1997, 11:1059-1066.
37. Kuhn M. Function and dysfunction of mammalian membrane guanylyl cyclase receptors: lessons from genetic mouse models and implications for human diseases. cGMP: generators, effectors and therapeutic implications 2009, 47-69. Springer, Berlin Heidelberg. S. HHHW, F. Hofmann, J.P. Stasch (Eds.).
38. McWilliams V, Whiteside G, McKeage K. Linaclotide. Drugs 2012, 72:2167-2175.
39. Busby RW, Bryant AP, Bartolini WP, Cordero EA, Hannig G, Kessler MM, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 2010, 649:328-335.
40. Johnston JM, Kurtz CB, Drossman DA, Lembo AJ, Jeglinski BI, MacDougall JE, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009, 104:125-132.
41. Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther 2013, 344:196-206.
42. Shailubhai K. Therapeutic applications of guanylate cyclase-C receptor agonists. Curr Opin Drug Discov Devel 2002, 5:261-268.
43. Shailubhai K, Comiskey S, Foss JA, Feng R, Barrow L, Comer GM, et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci 2013, 58:2580-2586.
44. Shailubhai K, Barrow L, Talluto C, Comiskey S, Foss J, Feng R, et al. Plecanatide, a guanylate cyclase C agonist improves bowel habits and symptoms associated with chronic constipation in a phase IIa clinical study. Am J Gastroenterol 2011, 106:S502.
45. Pattni S, Walters JR. Recent advances in the understanding of bile acid malabsorption. Br Med Bull 2009, 92:79-93.
46. Bazzoli F, Malavolti M, Petronelli A, Barbara L, Roda E. Treatment of constipation with chenodeoxycholic acid. J Int Med Res 1982, 11:120-123.
47. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, Burton D, Carlson P, Busciglio IA, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010, 8:159-165.
48. Rao AS, Wong BS, Camilleri M, Odunsi-Shiyanbade ST, McKinzie S, Ryks M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010, 139:1549-1558.
49. Chey WD, Camilleri M, Chang L, Rikner L, Graffner H. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 2011, 106:1803-1812.
50. Wong BS, Camilleri M. Elobixibat for the treatment of constipation. Expert Opin Investig Drugs 2013, 22:277-284.
51. Maneerattanaporn M, Chey WD. Targeting bile acids in the treatment of constipation. Expert Rev Gastroenterol Hepatol 2011, 5:657-659.
52. Sakamoto S, Kusuhara H, Miyata K, Shimaoka H, Kanazu T, Matsuo Y, et al. Glucuronidation converting methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) to a potent apical sodium-dependent bile acid transporter inhibitor, resulting in a hypocholesterolemic action. J Pharmacol Exp Ther 2007, 322:610-618.
53. Li H, Xu GR, Shang Q, Pan LX, Shefer S, Batta AK, et al. Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7α-hydroxylase. Metabolism 2004, 53:927-932.
54. West KL, Zern TL, Butteiger DN, Keller BT, Fernandez ML. SC-435, an ileal apical sodium co-dependent bile acid transporter (ASBT) inhibitor lowers plasma cholesterol and reduces atherosclerosis in guinea pigs. Atherosclerosis 2003, 171:201-210.
55. Jia G, Meng MB, Huang ZW, Qing X, Lei W, Yang XN, et al. Treatment of functional constipation with the Yun-chang capsule: a double-blind, randomized, placebo-controlled, dose-escalation trial. J Gastroenterol Hepatol 2010, 25:487-493.
56. Cheng CW, Bian ZX, Zhu LX, Wu JC, Sung JJ. Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation. Am J Gastroenterol 2010, 106:120-129.
57. - secretion across rat distal colonic mucosa. J Ethnopharmacol 2011, 134:406-413.
58. Mozaffari S, Didari T, Nikfar S, Abdollahi M. Phase II drugs under clinical investigation for the treatment of chronic constipation. Expert Opin Investig Drugs 2014, 23:1485-1497.
59. Charmot D. Non-systemic drugs: a critical review. Curr Pharm Des 2012, 18:1434-1445.
60. Jacques V, Melisi M, Shen L, McCauley D, Shacham S, Jones S. EPX-16006-a highly selective P2Y2 agonist reduces gastrointestinal transit time. Am J Gastroenterol 2008, 103:S480-S481.
61. Rachmilewitz D, Karmeli F. Effect of colchicine on jejunal adenylate cyclase activity, PGE2 and cAMP contents. Eur J Pharmacol 1980, 67:235-239.
62. Verne GN, Davis RH, Robinson ME, Gordon JM, Eaker EY, Sninksy CA. Treatment of chronic constipation with colchicine: randomized, double-blind, placebo-controlled, crossover trial. Am J Gastroenterol 2003, 98:1112-1116.
63. Taghavi SA, Shabani S, Mehramiri A, Eshraghian A, Kazemi SM, Moeini M, et al. Colchicine is effective for short-term treatment of slow transit constipation: a double-blind placebo-controlled clinical trial. Int J Colorectal Dis 2010, 25:389-394.